These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11083364)

  • 41. Early Life Health Interventions and Academic Achievement.
    Bharadwaj P; Loken KV; Neilson C
    Am Econ Rev; 2013 Aug; 103(5):1862-91. PubMed ID: 29533048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
    Mazela J; Merritt TA; Gadzinowski J; Sinha S
    Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surfactant status in preterm neonates recovering from respiratory distress syndrome.
    Verlato G; Cogo PE; Balzani M; Gucciardi A; Burattini I; De Benedictis F; Martiri G; Carnielli VP
    Pediatrics; 2008 Jul; 122(1):102-8. PubMed ID: 18595992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Lung function in premature infants can be improved. Surfactant therapy and CPAP reduce the need of respiratory support].
    Blennow M; Jonsson B; Dahlström A; Sarman I; Bohlin K; Robertson B
    Lakartidningen; 1999 Mar; 96(13):1571-6. PubMed ID: 10218338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surfactant therapy in the USA: trials and current routines.
    Soll RF
    Biol Neonate; 1997; 71 Suppl 1():1-7. PubMed ID: 9209741
    [No Abstract]   [Full Text] [Related]  

  • 46. Surfactant replacement therapy.
    Yu V
    Indian Pediatr; 1998 Nov; 35(11):1081-96. PubMed ID: 10216542
    [No Abstract]   [Full Text] [Related]  

  • 47. Survival and follow-up of infants born at 23 to 26 weeks of gestational age: effects of surfactant therapy.
    Ferrara TB; Hoekstra RE; Couser RJ; Gaziano EP; Calvin SE; Payne NR; Fangman JJ
    J Pediatr; 1994 Jan; 124(1):119-24. PubMed ID: 8283360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Surfactant therapy in extremely premature infants.
    Bose C; McCaffrey M
    J Pediatr; 1994 Jul; 125(1):173; author reply 173-4. PubMed ID: 8021776
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of singleton and multiple-birth outcomes of infants born at or before 32 weeks of gestation.
    Qiu X; Lee SK; Tan K; Piedboeuf B; Canning R;
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):365-71. PubMed ID: 18238974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enteral feeding practices in very preterm infants: an international survey.
    Klingenberg C; Embleton ND; Jacobs SE; O'Connell LA; Kuschel CA
    Arch Dis Child Fetal Neonatal Ed; 2012 Jan; 97(1):F56-61. PubMed ID: 21856644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exogenous surfactant therapy in newborns.
    Rodriguez RJ; Martin RJ
    Respir Care Clin N Am; 1999 Dec; 5(4):595-616. PubMed ID: 10565883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surfactant therapy in neonatal respiratory distress syndrome.
    Nagesh K; Bhat V; Kunikullaya S; Rajesh N
    Indian Pediatr; 1994 Aug; 31(8):971-7. PubMed ID: 7883350
    [No Abstract]   [Full Text] [Related]  

  • 54. [Surfactant replacement therapy in neonatal respiratory distress syndrome: prophylactic therapy versus treating of established disease].
    Lubetzky R; Dolberg S
    Harefuah; 1999 Nov; 137(10):464-7. PubMed ID: 10959346
    [No Abstract]   [Full Text] [Related]  

  • 55. [Neonatal pediatrics in Denmark. Therapeutic routines in care of very low birth weight infants and very premature infants, 1990].
    Knudsen JL; Kamper J; Lenstrup C
    Ugeskr Laeger; 1993 May; 155(22):1687-90. PubMed ID: 8317009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic consequences of surfactant therapy.
    Eidelman AI
    J Perinatol; 1993; 13(2):137-9. PubMed ID: 8515307
    [No Abstract]   [Full Text] [Related]  

  • 57. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants.
    Proquitté H; Dushe T; Hammer H; Rüdiger M; Schmalisch G; Wauer RR
    Respir Med; 2007 Jan; 101(1):169-76. PubMed ID: 16698258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The extremely preterm births in Florence.
    Bertini G
    Arch Dis Child Fetal Neonatal Ed; 2009 May; 94(3):F231-2. PubMed ID: 19383862
    [No Abstract]   [Full Text] [Related]  

  • 59. Lowest effective dose of dexamethasone in the respiratory care of very preterm infants.
    Tsukahara H; Mayumi M
    Early Hum Dev; 2007 Jan; 83(1):3. PubMed ID: 16725285
    [No Abstract]   [Full Text] [Related]  

  • 60. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.